AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs

Reuters2021-09-23

LONDON, Sept 23 (Reuters) - AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial College London’s experimental COVID-19 vaccine to develop and sell drugs based on its self-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Leo_T
2021-09-23
Leo_T
Like pls. Tks
- Dirui:
  Ok
- VictorLin:
  Like
bostonxsgp
2021-09-23
bostonxsgp
Nice
- bostonxsgp:
  ok
咩咩虎
2021-09-23
咩咩虎
Nice
- 咩咩虎:
  Kk
- bostonxsgp:
  yes

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1158262650?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-09-23 14:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158262650","market":"us","top_or_hot":-1,"title":"AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs","media":"Reuters","content":"<div>\n<p>LONDON, Sept 23 (Reuters) - AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial College London’s experimental COVID-19 vaccine to develop and sell drugs based on its self-...</p>\n\n<a href=\"https://www.reuters.com/article/health-coronavirus-astrazeneca-imperial/astrazeneca-invests-in-imperials-self-amplifying-rna-technology-with-eye-on-future-drugs-idUSL8N2QO4JM\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-23 14:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/health-coronavirus-astrazeneca-imperial/astrazeneca-invests-in-imperials-self-amplifying-rna-technology-with-eye-on-future-drugs-idUSL8N2QO4JM><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LONDON, Sept 23 (Reuters) - AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial College London’s experimental COVID-19 vaccine to develop and sell drugs based on its self-...</p>\n\n<a href=\"https://www.reuters.com/article/health-coronavirus-astrazeneca-imperial/astrazeneca-invests-in-imperials-self-amplifying-rna-technology-with-eye-on-future-drugs-idUSL8N2QO4JM\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"https://www.reuters.com/article/health-coronavirus-astrazeneca-imperial/astrazeneca-invests-in-imperials-self-amplifying-rna-technology-with-eye-on-future-drugs-idUSL8N2QO4JM","article_id":"1158262650","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158262650","pubTimestamp":1632377121,"sourceInfo":null,"weMediaInfo":null,"summary":"LONDON, Sept 23 (Reuters) - AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial ","collect":0,"end_time":0,"defaultTopTitle":"reuters.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"阿斯利康投资帝国理工学院自扩增RNA技术着眼于未来药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9},"content_text":"LONDON, Sept 23 (Reuters) - AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial College London’s experimental COVID-19 vaccine to develop and sell drugs based on its self-amplifying RNA technology platform in other disease areas.\nUnder the deal, VaxEquity, a startup founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met, in addition to royalties on approved drugs and equity investment from AstraZeneca and life sciences investor Morningside Ventures.\nAstraZeneca already produces an adenoviral vector COVID-19 vaccine, and emphasised the potential of the self-amplifying RNA (saRNA) technology in novel therapeutic programmes beyond the coronavirus pandemic.\n“This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox,” said AstraZeneca research chief Mene Pangalos.\nThe technology works in a similar way to the messenger RNA (mRNA) vaccines made by Pfizer/BioNTech and Moderna.\nHowever, a self-amplifying RNA vaccine not only encodes the instructions for the host cell to make a coronavirus protein, but makes lots of copies of the RNA containing those instructions, meaning doses can be smaller and cheaper.\n“It’s a bit like having a manufacturing facility, and instead of having one copy of the recipe, you have multiple copies that you can hand round to multiple production lines within the cell to produce more protein,” Imperial’s Shattock told Reuters. “So that’s why it has that opportunity to use lower doses.”\nImperial’s COVID-19 vaccine is being retooled to produce a more consistent immune response with an eye on future coronavirus variants.\nAstraZeneca, under the deal, has the option to collaborate on 26 drug targets for use against other therapeutic areas like cancers and rare genetic diseases.\n“We believe self-amplifying RNA, once optimised, will allow us to target novel pathways not amenable to traditional drug discovery across our therapy areas of interest,” Pangalos said.\nU.S. companies Gritstone bio and Arcturus also are developing saRNA COVID-19 vaccines.\nShattock said safety data had been encouraging from initial trials of its COVID-19 vaccine, released in July ahead of peer review, and that Phase I results of its refined vaccine would be ready early next year.\n“The reason we were slower was because we were coming from an academic setting,” he said. “If we had this relationship (with AstraZeneca) at the beginning of 2020, we might have been faster.”","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":863841531,"gmtCreate":1632377685323,"gmtModify":1632800793888,"author":{"id":"3577164655493669","authorId":"3577164655493669","name":"Leo_T","avatar":"https://static.tigerbbs.com/4639e7c3fcdc38b65d6833798171bf2d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577164655493669","authorIdStr":"3577164655493669"},"htmlText":"Like pls. Tks","listText":"Like pls. Tks","text":"Like pls. Tks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/863841531","repostId":1158262650,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5969019,"gmtCreate":1632377774816,"gmtModify":1634788289865,"authorId":3576728357666184,"author":{"id":3576728357666184,"idStr":"3576728357666184","authorId":3576728357666184,"name":"Dirui","avatar":"https://static.tigerbbs.com/028fdb43f6018331c0e01e03918d42c9","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":863841531,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5969086,"gmtCreate":1632378917521,"gmtModify":1634788284498,"authorId":3561029602854131,"author":{"id":3561029602854131,"idStr":"3561029602854131","authorId":3561029602854131,"name":"VictorLin","avatar":"https://static.tigerbbs.com/8fd797c0a3e81d0a5a149ede57c53dc2","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":863841531,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"EN"},{"id":863841169,"gmtCreate":1632377634551,"gmtModify":1632800794135,"author":{"id":"3584157491931754","authorId":"3584157491931754","name":"bostonxsgp","avatar":"https://static.tigerbbs.com/55d82efabeabddb18cc2d6ca7a71a36f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584157491931754","authorIdStr":"3584157491931754"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/863841169","repostId":1158262650,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5969014,"gmtCreate":1632377652183,"gmtModify":1634788290190,"authorId":3584157491931754,"author":{"id":3584157491931754,"idStr":"3584157491931754","authorId":3584157491931754,"name":"bostonxsgp","avatar":"https://static.tigerbbs.com/55d82efabeabddb18cc2d6ca7a71a36f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":863841169,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":863849667,"gmtCreate":1632377458159,"gmtModify":1632800795368,"author":{"id":"3568542354994015","authorId":"3568542354994015","name":"咩咩虎","avatar":"https://static.tigerbbs.com/a6663bef57eca539a2c52ea184964654","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3568542354994015","authorIdStr":"3568542354994015"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/863849667","repostId":1158262650,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5968998,"gmtCreate":1632377463616,"gmtModify":1634788291276,"authorId":3568542354994015,"author":{"id":3568542354994015,"idStr":"3568542354994015","authorId":3568542354994015,"name":"咩咩虎","avatar":"https://static.tigerbbs.com/a6663bef57eca539a2c52ea184964654","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":863849667,"type":1,"supId":0,"prevId":0,"content":"Kk","text":"Kk","html":"Kk"},{"id":5969011,"gmtCreate":1632377644922,"gmtModify":1634788290517,"authorId":3584157491931754,"author":{"id":3584157491931754,"idStr":"3584157491931754","authorId":3584157491931754,"name":"bostonxsgp","avatar":"https://static.tigerbbs.com/55d82efabeabddb18cc2d6ca7a71a36f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":863849667,"type":1,"supId":0,"prevId":0,"content":"yes","text":"yes","html":"yes"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":37,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158262650"}